Kostantinos Alataris

Konstantinos Alataris, Ph.D.

President and Chief Executive Officer

Dr. Alataris has served as our President and Chief Executive Officer since January 2016. Previously, Dr. Alataris served as Zosano’s President and Chief Operating Officer. Dr. Alataris was the Founder and held the roles of President, Chief Executive Officer and Chief Commercial Officer with Nevro Corp. (NYSE:NVRO), a company that developed an innovative, evidence-based neuromodulation platform for the treatment of chronic pain. Under Dr. Alataris’ leadership, Nevro advanced from product concept to clinical testing to successful market launch and international commercialization. Dr. Alataris has also served as Executive Chairman of the Board of Directors at IRRAS AB, a CNS medical device and drug delivery company and Head of Digital Healthcare Strategy at mc10inc a wearable sensor company. Prior to Nevro, he was Vice President at Bay City Capital, a healthcare focused venture capital firm based in San Francisco. He holds Master’s degrees in Science and Business and a Ph.D. in Bioengineering with emphasis in Neuroscience from the University of Southern California.

 

Peter Daddona, Ph.D.

Scientific Advisor,
Former Chief Scientific Officer and Executive Vice President, Research & Development

Peter E. Daddona has served as the company’s scientific advisor since January 1, 2016 and prior to that he was Chief Scientific Officer and Executive Vice President, Research and Development since 2006, and as a member of our board of directors since the inception of Zosano Pharma Corporation (then named ZP Holdings, Inc.) in January 2012. Dr. Daddona has also served as Chief Scientific Officer of Zosano Pharma since July 31, 2006. Dr. Daddona founded Zosano Pharma in 2006 as a spin-off of Johnson & Johnson, prior to which he served as Vice President, Scientific Leader and Board member of The Macroflux(r) Internal Venture at Johnson & Johnson. Previously, Dr. Daddona was Vice President of Macroflux(r) Technology Development and Biological Sciences and served on the Strategic Product Portfolio Review Committee at ALZA Corporation in Mountain View, California, and held an appointment as Consulting Associate Professor of Dermatology at Stanford University. Before joining ALZA, Dr. Daddona served as Vice President, Immunobiology Research at Centocor, where he focused on preclinical development of therapeutic monoclonal antibodies. Prior to joining Centocor, Dr. Daddona served as Associate Professor of Biological Chemistry and Internal Medicine at the University of Michigan. Dr. Daddona earned his Ph.D. from the University of Connecticut and completed post-doctoral training at Duke University.

 

Thorsten von Stein, M.D., Ph.D.

Chief Medical Officer

Dr. von Stein resumes his former role at Zosano as Chief Medical Officer having previously served in that position from 2009 to 2014. Before joining Zosano, Dr. von Stein served at Tercica as Senior Vice President and Chief Medical Officer from 2005 to 2009. From 2001 to 2005, he served as Chief Medical Officer and previously Vice President of Clinical Development at NeurogesX. Dr. von Stein held positions of increasing responsibility in clinical development and project management from 1994 to 2001 at Roche Palo Alto and F. Hoffmann-La Roche AG in Basel, Switzerland. Dr. von Stein received his medical degree from Munich University, Germany, and his Ph.D. in Computer Science from the University of Hamburg, Germany.

 

Laxmi Peri

Senior Vice President, Operations

Laxmi Peri joins Zosano after 11 years as Vice President, R&D at Thoratec Corporation, a world leader in research, development and manufacturing of medical devices for circulatory support. At Thoratec, Mr. Peri was a part of the executive team that grew the business from revenues of $100 million to more than $500 million in a span of ten years. Prior to joining Thoratec, Mr. Peri was with St. Jude Medical for ten years in a variety of leadership positions in operations management and R&D. He has extensive experience in process development, product development and manufacturing management. Mr. Peri holds an M.B.A. from the University of Minnesota, and a B.S. and an M.S. in Mechanical Engineering.

 
Winnie Tso

Winnie Tso

Chief Financial Officer

Winnie W. Tso joined Zosano as the company's Chief Financial Officer in April, 2014. Prior to joining Zosano Pharma, Ms. Tso served as Vice President, Finance and Corporate Controller of SciClone Pharmaceuticals, a publicly-traded specialty biopharmaceutical company, in 2013. Ms. Tso has served in various Vice President and Principal Accounting Officer positions from 2009 to 2013, including her role at Velti plc where Ms. Tso helped lead Velti’s U.S. public offering, raising in excess of $150 million in equity financing. Prior to Velti, Ms. Tso held senior finance positions at several publicly-traded biopharmaceutical companies, including ARYx Therapeutics, Titan Pharmaceuticals and Genelabs Technologies, where she was responsible for building the finance and accounting infrastructures and implementing systems of internal controls. Ms. Tso is a Certified Management Accountant, a Certified Financial Manager, a Certified Public Accountant licensed in the State of California and a member of the American Institute of Certified Public Accountants. Ms. Tso earned her B.S. degree in Business Administration from the Haas School of Business at the University of California, Berkeley.

 
Contact   |   Sitemap   |   Legal
  |   Design: Formative